TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07801066: A Prospective, Randomized, Single-blind, Study to Assess Drowsiness, Cognition, Fall Risk, and Electroencephalographic (EEG) Dynamics After Oral Metaxalone Tablets 640 mg (M640) Versus Metaxalone 800 mg in Healthy Partic

Sponsor: Primus Pharmaceuticals · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$743,680

Rescue Site Savings

+$478,080

Unlock Full NCT07801066 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07801066 Rescue Dossier →